about
Mass drug administration for trachoma: how long is not long enough?Integrating data and resources on neglected tropical diseases for better planning: the NTD mapping tool (NTDmap.org)Hepatitis B Virus Incidence and Risk Factors Among Human Immunodeficiency Virus-1 Negative Men Who Have Sex With Men in KenyaUniversity students and HIV in Namibia: an HIV prevalence survey and a knowledge and attitude survey.Diagnostic Accuracy of the HemoCue Hb 301, STAT-Site MHgb and URIT-12 Point-of-Care Hemoglobin Meters in a Central Laboratory and a Community Based Clinic in Durban, South AfricaViral complementation allows HIV-1 replication without integration.Cellular immune responses during high-dose interferon-alpha induction therapy for hepatitis C virus infection.Prediction of virologic response in difficult-to-treat chronic hepatitis C patients during high-dose interferon induction therapy.Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3.4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a.Transient reappearance of serum hepatitis C virus RNA observed by real-time PCR during antiviral therapy with peginterferon and ribavirin: Reappearance of references published in 2005-2009.Low-level HCV viraemia after initial response during antiviral therapy: transcription-mediated amplification predicts treatment failure.Hepatitis C virus RNA quantification by the COBAS AmpliPrep/COBAS TaqMan System: averages do not tell the whole story.Monocyte-derived dendritic cells from chronic HCV patients are not infected but show an immature phenotype and aberrant cytokine profile.Factor XIII Val34Leu mutation accelerates the development of fibrosis in patients with chronic hepatitis B and C.High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection.Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial
P50
Q28544875-1BCB3307-AB3E-4C9B-9694-B221BB89668AQ28650428-A5FA18EC-1409-4727-BB01-8C8139FE88DFQ33878681-605A028C-6CC2-4CE0-AC00-7DFA0C5F3490Q35819632-79FCE4B6-510A-4E85-8FE5-091DFCB9887AQ35980036-BE366F25-D761-4FB6-A94E-EDA20EAA19C0Q39963401-3F881495-9C0D-4D53-A3EA-698118917BA0Q42162228-EDE8AD4E-8977-447B-B120-F14BAB0337E3Q42979490-DAC0A27D-D858-4C9F-B299-421DD78966CFQ42979765-C87FF268-498F-48F5-AFA9-A41561551EB4Q42995867-1BA5BF72-471D-4AD2-A3E7-A556AFE5DFFDQ43038692-B63A7089-3C53-408E-8C1D-E8F44887AEF3Q43038832-759CD675-1B60-40BC-9563-F4D227712698Q43040011-081BC957-1C88-4748-A884-3A2E128A9C59Q44703656-382A8FA1-AFCB-49D1-9DFC-E03B37FCE1A6Q45399117-2275C7BF-300B-497D-9B5C-071C3021AF00Q64088191-B91C7986-13D3-4FF2-A630-E893CAECADF7
P50
name
Huub C Gelderblom
@en
type
label
Huub C Gelderblom
@en
prefLabel
Huub C Gelderblom
@en